Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more
Market Cap & Net Worth: Oxford Biomedica plc (OXBDF)
Oxford Biomedica plc (PINK:OXBDF) has a market capitalization of $448.36 Million ($448.36 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #14537 globally and #5831 in its home market, demonstrating a -4.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oxford Biomedica plc's stock price $3.71 by its total outstanding shares 120852209 (120.85 Million).
Oxford Biomedica plc Market Cap History: 2015 to 2025
Oxford Biomedica plc's market capitalization history from 2015 to 2025. Data shows change from $483.41 Million to $448.36 Million (-2.80% CAGR).
Oxford Biomedica plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oxford Biomedica plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.88x
Oxford Biomedica plc's market cap is 4.88 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $483.41 Million | $15.91 Million | -$13.02 Million | 30.39x | N/A |
| 2016 | $253.79 Million | $27.78 Million | -$16.64 Million | 9.14x | N/A |
| 2017 | $664.69 Million | $37.59 Million | -$9.02 Million | 17.68x | N/A |
| 2018 | $1.07 Billion | $66.78 Million | $7.54 Million | 16.04x | 142.07x |
| 2019 | $1.07 Billion | $64.06 Million | -$16.07 Million | 16.70x | N/A |
| 2020 | $1.72 Billion | $87.73 Million | -$6.25 Million | 19.58x | N/A |
| 2021 | $2.02 Billion | $142.80 Million | $19.01 Million | 14.12x | 106.07x |
| 2022 | $630.85 Million | $139.99 Million | -$39.16 Million | 4.51x | N/A |
| 2023 | $325.09 Million | $89.54 Million | -$157.49 Million | 3.63x | N/A |
| 2024 | $628.43 Million | $128.80 Million | -$43.19 Million | 4.88x | N/A |
Competitor Companies of OXBDF by Market Capitalization
Companies near Oxford Biomedica plc in the global market cap rankings as of March 18, 2026.
Key companies related to Oxford Biomedica plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oxford Biomedica plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Oxford Biomedica plc's market cap moved from $483.41 Million to $ 448.36 Million, with a yearly change of -2.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $448.36 Million | -28.65% |
| 2024 | $628.43 Million | +93.31% |
| 2023 | $325.09 Million | -48.47% |
| 2022 | $630.85 Million | -68.71% |
| 2021 | $2.02 Billion | +17.42% |
| 2020 | $1.72 Billion | +60.56% |
| 2019 | $1.07 Billion | -0.17% |
| 2018 | $1.07 Billion | +61.18% |
| 2017 | $664.69 Million | +161.90% |
| 2016 | $253.79 Million | -47.50% |
| 2015 | $483.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oxford Biomedica plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $448.36 Million USD |
| MoneyControl | $448.36 Million USD |
| MarketWatch | $448.36 Million USD |
| marketcap.company | $448.36 Million USD |
| Reuters | $448.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.